Topics

Bio-Thera, an Antibody Company, Prices $241 Million Shanghai STAR Board IPO

01:37 EST 12 Feb 2020 | ChinaBio Today

Bio-Thera Solutions of Guangzhou priced its IPO on Shanghai’s STAR Board to raise $241 million at a valuation of almost $2 billion. The offering, which placed 60 million shares at RMB32.76 each, was reported to be 3,225 times oversubscribed. Bio-Thera lists ten antibody candidates in its pipeline. The company develops novel antibodies (6) and biosimilars (4) for oncology and autoimmune indications. In January, the company's Humira biosimilar was approved for China use, its first commercialization approval. More details....

Stock Symbol: (SHA: 688177)

Share this with colleagues:

Original Article: Bio-Thera, an Antibody Company, Prices $241 Million Shanghai STAR Board IPO

NEXT ARTICLE

More From BioPortfolio on "Bio-Thera, an Antibody Company, Prices $241 Million Shanghai STAR Board IPO"

Quick Search

Relevant Topics

Antibodies
An antibody is a protein produced by the body's immune system when it detects harmful substances, called antigens. Examples of antigens include microorganisms (such as bacteria, fungi, parasites, and viruses) and chemicals. Antibodies may be produc...

Biotechnology Products
BioPortfolio lists over 550 biotechnology products - please open http://www.bioportfolio.com/channels?category_id=5 Direct topic pages: Actos Advair Biopharmaceuticals Biosimilars Biotherapeutics GMO Crops Lipitor ...

Cancer
  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...